Lytix Biopharma ASA · OSL:LYTIX
Lytix Biopharma ASA — Q4 2024 Earnings Presentation
32 slides from Lytix Biopharma ASA's earnings presentation, Feb 13, 2025
Slide 1: Developing the future of cancer treatment
Developing the future of cancer treatment Fighting cancer by local killing of tumor cells and activation of the immune system Q4 2024 results presentation 13.02.2025 1
Slide 2: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by Lytix Biopharma AS ("Company") exclusively for information purposes. The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated (’relevant persons’). Any person
Slide 3: Presenting team
Presenting team Øystein Rekdal, CEO Co-founder of Lytix Biopharma, Dr. Rekdal has served as CEO twice, most recently since 2019. With a PhD in tumor immunology, his expertise in anticancer molecules from host defense peptides underpins Lytix's technology. He is a regular speaker at international onc
Slide 4: Company introduction
Company introduction DC lytix
Slide 5: Lytix Biopharma approaching commercialization and the final step
Lytix Biopharma approaching commercialization and the final step Novel, unique and Robust portfolio of Strong phase II results in innovative technology clinical studies basal cell carcinoma Lytix technology already proven Targeting different types of skin Led by licensing partner Verrica cancer Phar
Slide 6: Lytix is addressing the major shortcomings in current cancer immunotherapy
Lytix is addressing the major shortcomings in current cancer immunotherapy MALIGNANT MELANOMA CHALLENGE Majority of cancer patients lack immune cells in the tumors and therefore don’t respond to current immunotherapy NON- RESPONDERS Lytix technology enhance the number of immune SOLUTION 60% 67% No/f
Slide 7: Lytix's solution works through two phases
Lytix’s solution works through two phases; killing tumors locally and activating a systemic broad immune response 7
Slide 8: Q4 Highlights
Q4 Highlights DC lytix
Slide 9: Highlights for the fourth quarter (I/II)
Waiting on last update from ATLAS-IT-05 Highlights for the fourth quarter (I/II) - And post quarter end Solid results in ph. II BCC study with licensing partner Verrica Pharmaceuticals – Ph. III next step • Impressive 97% calculated objective response rate, with overall reduction in tumor size of 86
Slide 10: Highlights for the fourth quarter (II/II)
Highlights for the fourth quarter (II/II) - And post quarter end The new superior formulation of LTX-401 may represent a significant advancement for Lytix’s second lead candidate. • This new formulation of LTX-401 has demonstrated substantially improved anticancer effects, with the added benefit of
Slide 11: Clinical/Operational update
Clinical/Operational update
Slide 12: Clinical progress
Clinical progress Product candidate Study/partner Indication Discovery Phase I Phase II Phase III Melanoma patients progressed on checkpoint ATLAS-IT-05 inhibitors Phase II In combination with Keytruda® Verrica LTX-315 Basal cell carcinoma Phase II Phase III TBD H1 ‘25 Pharmaceuticals Neoadjuvant Ea
Slide 13: Phase II study: Basal cell carcinoma (Verrica Pharmaceuticals)
Clinical/Operational update 1 Phase II study: Basal cell carcinoma (Verrica Pharmaceuticals)
Slide 14: LTX-315: A potential paradigm shift in treatment of BCC
Study: Verrica Ph. II Completed LTX-315: A potential paradigm shift in treatment of BCC BCCs typically found in skin exposed to sun ~80% located on the face and head Current treatment options are invasive ~95 % of BCC patients treated with surgery Before After Surgery can cause pain or discomfort, b
Slide 15: Commercially validated through partnering with Verrica Pharmaceuticals
Commercially validated through partnering with Verrica Pharmaceuticals RECENT DEVELOPMENTS The partnership The partnership • LTX-315 (VP-315) remains a core asset for both Verrica and Lytix with positive phase II results in BCC and melanoma, respectively for each company. → Verrica Pharmaceuticals h
Slide 16: Phase II study: Late stage melanoma (ATLAS-IT-05)
Clinical/Operational update 1 Phase II study: Late stage melanoma (ATLAS-IT-05)
Slide 17: ATLAS-IT-05 (ongoing): Promising effects of LTX-315 in late-stage melanoma
Study: ATLAS-IT-05 (ongoing): Promising effects of ATLAS-IT-05 Ongoing LTX-315 in heavily pre-treated patients with late-stage melanoma Complete regression in non-injected tumors Complete regression in injected tumors ! Before Treatment Positive interim data from 20 evaluable patients Baseline scan
Slide 18: New phase II study: Early stage melanoma (NeoLIPA)
Clinical/Operational update 1 New phase II study: Early stage melanoma (NeoLIPA)
Slide 19: NeoLIPA – Expanding the potential of LTX-315
Study: NeoLIPA NeoLIPA – Expanding the potential of LTX- Started 315 Study Overview • Evaluate LTX-315 in combination with pembrolizumab (PD-1 inhibitor), administered prior to surgery, in early-stage patients with a responsive immune system • Dual mode of action, in which LTX-315 can shrink tumors
Slide 20: LTX-401
Clinical/Operational update 1 LTX-401
Slide 21: LTX-401 – a small oncolytic molecule with a large commercial potential
LTX-401 – a small oncolytic molecule with a large commercial potential, including deep-seated cancer LTX-401 approaching Small molecule Similar mode-of-action as LTX-315 clinical stage with superior effects in liver cancer models • Increased commercial interest with a clinical Significant commercial
Slide 22: Financials and outlook
Financials and outlook DC lytix
Slide 23: Key figures – profit and loss
Key figures – profit and loss Amounts in NOK ‘000 Q4 2024 Q4 2023 H2 2024 H2 2023 FY 2024 FY 2023 Total operating income 377 - 607 3,917 11,134 3,991 Total operating expenses (32,998) (19,581) (56,278) (42,118) (107,029) (100,776) Loss from operations (32,622) (19,581) (55,671) (38,201) (95,896) (96
Slide 24: Strengthened financial position going into 2025
Strengthened financial position going into 2025 Total operating expenses Cash and short-term financial investments 34,209 130 791 32,998 126 371 100 218 24,448 23,280 22,537 21,540 20,009* 78 767 19,581 60 181 50 548 24,389 43,529 22,894 15,183 10,643 16,315 26 172 12,952 10,984* 13,170 Q1 23 Q2 23
Slide 25: Key figures – balance sheet
Key figures – balance sheet Amounts in NOK ‘000 30.06.2024 30.09.2024 31.12.2024 31.12.2023 Assets Property, plant and equipment 76 59 42 110 Right-of-use assets 2,998 2,793 2,589 438 Trade and other receivables 14,410 9,902 13,113 12,777 Short-term financial investments - - - 23,183 Cash and cash e
Slide 26: Lytix Biopharma's roadmap to create shareholder value
Lytix Biopharma’s roadmap to create shareholder value Neoadjuvant melanoma Non-metastatic skin cancer and breast Deep seated cancer LTX-315: Clear path towards LTX-315: Phase II results in LTX-401: Phase I study in deep commercialization, demonstrated NeoLIPA seated tumors (2026) through licensing w
Slide 27: Executing on our strategy – upcoming events
Executing on our strategy – upcoming events Verrica - BCC ‒ Clinical Study Report (H1 2025) ‒ Analysis of Immune responses (Q1 2025) ‒ FDA- End of Phase 2 meeting (H1 2025) Lytix Clinical Development ‒ Interim results from NeoLIPA (H2 2025) ‒ LTX-401 Phase 1 ready (Q4 2026) ‒ Finalization of ATLAS-I
Slide 28: Q&A
Q&A DC lytix
Slide 29: Interim financial statements
Interim financial statements
Slide 30: Condensed interim statement of profit and loss
Condensed interim statement of profit and loss Unaudited Unaudited Unaudited Unaudited Unaudited Amounts in NOK thousands Q4 2024 Q4 2023 H2 2024 H2 2023 FY 2024 FY 2023 Revenue 377 - 607 3,917 11,134 3,991 Other operating income - - - - - - Total operating income 377 - 607 3,917 11,134 3,991 Payrol
Slide 31: Condensed interim statement of financial position
Condensed interim statement of financial position Unaudited Unaudited Unaudited Amounts in NOK thousands 30.06.2024 30.09.2024 31.12.2024 31.12.2023 Assets Non-current assets Property, plant and equipment 76 59 42 110 Right-of-use assets 2,998 2,793 2,589 438 Total non-current assets 3,074 2,853 2,6
Slide 32: Condensed interim statement of cash flows
Condensed interim statement of cash flows Unaudited Unaudited Unaudited Unaudited Unaudited Amounts in NOK thousands Q4 2024 Q4 2023 H2 2024 H2 2023 FY 2024 FY 2023 Cash flows from operating activities Loss for the period (31,910) (18,566) (54,648) (36,803) (94,265) (87,897) Adjustments for: Depreci